San Francisco – July 14, 2026 – Cooley advised Jefferies and Wedbush as the placement agents to Avere Therapeutics, a privately held biotechnology company advancing oral therapies for IL-23 driven inflammatory diseases, in connection with a $320 million private investment concurrent with its merger with NextCure. The private placement was led by Fairmount and Hansoh Pharmaceutical Group, with participation from Venrock Healthcare Capital Partners, General Atlantic, Janus Henderson Investors, Wellington Management, Boyu Capital, Sirona Capital, funds and accounts advised by T. Rowe Price Investment Management, RTW Investments, Sirenia Capital Management, Logos Capital, Redmile, Affinity Asset Advisors, Balyasny Asset Management, Wedbush Healthcare Partners and other institutional investors. Upon completion of the transaction, which is expected to occur in the second half of 2026, the combined company is expected to operate as Avere Therapeutics, Inc., and trade on Nasdaq under the ticker symbol AVRX.

Lawyers Denny Won, Charlie Kim, Div Gupta and Peter Haddad led the Cooley team advising the placement agents. The team also included Carol Laherty, Marcelo Pomeranz, Natasha Leskovsek, Phil Mitchell and Karen Tsai.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

Related Contacts

Denny Won
Partner
San Francisco
Charlie Kim
Partner
San Diego
Div Gupta
Partner
New York
Peter A. Haddad
Associate
San Diego
Dr. Carol Laherty
Partner
Seattle
Dr. Marcelo Pomeranz
Associate
San Diego
Natasha Leskovsek
Of Counsel
Washington, DC
Phil Mitchell
Senior Counsel
New York
Karen Tsai
Special Counsel
Washington, DC
Dr. Daniel Knauss
Partner
Palo Alto
Randy Sabett
Special Counsel
Washington, DC
Jennifer Shanley
Special Counsel
New York
Dr. Johnny Kozlowski
Patent Agent
San Diego

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.